Key facts
- It has raised $43.8M; the latest was Grant ($4.9M) in Aug 2024.
- Notable investors include Creative Destruction Lab, University of Toronto, Endless Frontier Labs, University of Toronto Entrepreneurship, InterVest — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for IMNEWRUN
- ·The full record, as it builds
Funding rounds
No funding rounds for IMNEWRUN are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About IMNEWRUN
Developer of a biotechnology company designed to advance new therapeutics for disorders of the central nervous system. The company offers integrated drug-discovery platforms combining artificial intelligence, structural biology and neuroscience research that creates new knowledge through learning opportunities from basic research to the clinic, enabling academic institutions and pharmaceutical companies to accelerate development of treatments for neurological diseases.
- Sector
- Business Products and Services (B2B)
- HQ
- Suwon, South Korea
- Founded
- 2019
- Employees
- 41
- Website
- imnewrun.com/
- Ownership
- Privately Held (backing)
IMNEWRUN doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in IMNEWRUN shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on IMNEWRUN in its N-PORT filings yet. We sweep new filings monthly.